DiaMedica Therapeutics (NASDAQ:DMAC) Releases Earnings Results, Meets Expectations

DiaMedica Therapeutics (NASDAQ:DMAC) announced its earnings results on Thursday. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21), FiscalAI reports.

DiaMedica Therapeutics Price Performance

DMAC stock traded down $0.33 on Thursday, reaching $9.33. 187,770 shares of the company traded hands, compared to its average volume of 201,430. DiaMedica Therapeutics has a one year low of $5.24 and a one year high of $11.00. The company has a market cap of $503.17 million, a P/E ratio of -12.96 and a beta of 0.95. The firm has a fifty day simple moving average of $8.11 and a 200-day simple moving average of $7.19.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Thursday, October 15th. Wall Street Zen raised shares of DiaMedica Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, DiaMedica Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $12.00.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.